Key result
Cyclosporin A reduced mGC-A activities by approximately 60% in ANF-treated LLC-PK1 cells through superoxide and/or peroxynitrite generated by NADH oxidase.
Why the study?
Cyclosporin A causes nephrotoxicity and hypertension, but the detailed mechanisms remain incompletely understood.
Answers are grounded in this paper and cite their sources.
Cyclosporin A inhibits ANF-stimulated mGC-A activities via NAD(P)H oxidase-generated superoxide or peroxynitrite, providing a potential mechanistic explanation for CsA-induced hypertension.
Cyclosporin A (CsA) is a common immunosuppressant wildly used in patients with organ transplant and autoimmune diseases; however, it can cause several adverse effects, such as nephrotoxicity and hypertension. The detailed mechanisms have not been completely understood. Atrial natriuretic factor (ANF) and its receptor (mGC-A) have been shown to play a crucial role in the regulation of blood pressure. Here, we investigated the effects of CsA on the activation of mGC-A in ANF-treated LLC-PK1 cells. In our study, ANF-induced mGC-A activities and superoxide generation in LLC-PK1 cells were measured by guanosine 3',5'-cyclic monophosphate (cGMP) radioimmunoassay and lucigenin-dependent chemiluminescence, respectively. We found that CsA can reduce about 60% of mGC-A activities in ANF-treated LLC-PK1 cells. CsA is known to induce superoxide. Addition of superoxide generators menadione and diamide mimicked the effects of CsA, whereas DPI (a reduced nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase inhibitor) and Tiron (a superoxide quencher) blocked the suppressive effects of CsA on ANF-induced mGC-A activities. We previously showed that the catalytic domain of GC-A (GC-c) expresses guanylate cyclase activities. Addition of menadione, diamide, or peroxynitrite or transfection of Nox-4 NAD(P)H oxidase abolished GC-c activities. In conclusion, CsA inhibits ANF-stimulated mGC-A activities through superoxide and/or peroxynitrite generated by an NAD(P)H oxidase by interacting with the catalytic domain of mGC-A.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2022) studied this question. Cyclosporin A vs. Control was evaluated on mGC-A activities (cGMP production) (p=<0.001). Cyclosporin A reduced mGC-A activities by approximately 60% in ANF-treated LLC-PK1 cells through superoxide and/or peroxynitrite generated by NADH oxidase.
Synapse has enriched 10 related papers. Consider them for comparative context: